Combined measurement of plasma cell proliferative and apoptotic index in multiple myeloma defines patients with good and poor prognosis

Jiri Minarik, Vlastimil Scudla, Marta Ordeltova, Tomas Pika, Jaroslav Bacovsky, Michael Steinbach, Vipin Kumar, Brian Van Ness

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

We assessed plasma cell proliferation (by propidium iodide index, PC-PI) and apoptosis (by annexin-V index PC-AI) for the estimation of overall survival (OS) in multiple myeloma (MM) patients. 181 patients with newly diagnosed MM were assessed, treated using conventional chemotherapy. The values best discriminating patients with poor prognosis were PC-PI. > 3.0% and PC-AI. < 4.75%, and for good prognosis PC-PI. ≤ 3.0% and PC-AI. ≥ 4.75%. The median OS was 8 months vs 40 months, p = 0.0002.Our results suggest that combined measurement of plasma cell proliferation and apoptosis creates a unique strong prognostic factor based on growth characteristics of the tumor clone.

Original languageEnglish (US)
Pages (from-to)44-48
Number of pages5
JournalLeukemia research
Volume35
Issue number1
DOIs
StatePublished - Jan 2011

Bibliographical note

Funding Information:
The study was supported by the grants of Ministry of Health of the Czech Republic (NR 9500-3 and 9489-3 ).

Keywords

  • Apoptosis
  • Multiple myeloma
  • Prognosis
  • Proliferation

Fingerprint Dive into the research topics of 'Combined measurement of plasma cell proliferative and apoptotic index in multiple myeloma defines patients with good and poor prognosis'. Together they form a unique fingerprint.

Cite this